

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 569 132 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
01.03.2000 Bulletin 2000/09

(51) Int. Cl.<sup>7</sup>: **C07F 13/00**, C07C 229/12,  
A61K 51/04, A61K 51/10,  
G01N 33/534

(21) Application number: **93302712.0**

(22) Date of filing: **07.04.1993**

**(54) Improvements in radiolabelling**

Verbesserungen and Radiomarkierung

Améliorations relatives au radiomarquage

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT  
SE**

(30) Priority: **02.05.1992 GB 9209641**

(43) Date of publication of application:  
**10.11.1993 Bulletin 1993/45**

(73) Proprietor: **AnorMED Inc.**  
**Langley BC V2Y 1N5 (CA)**

(72) Inventors:  
• **Bridger, Gary James**  
**Bryn Mawr, Pennsylvania 19010 (US)**  
• **Hernandez, Pedro Emilio**  
**Malvern, Pennsylvania 19356 (US)**  
• **Higgins, John David, III**  
**West Chester, Pennsylvania 19380 (US)**  
• **Larsen, Scott Kenneth**  
**West Chester, Pennsylvania 19380 (US)**

(74) Representative:  
**W.P. THOMPSON & CO.**  
**Coopers Building,**  
**Church Street**  
**Liverpool L1 3AB (GB)**

(56) References cited:  
**EP-A- 0 384 769** **US-A- 4 772 724**

- **BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE** no. 5-6, 1975, pages 1160 - 1164  
**MIGHRI, Z. ET AL.**
- **CHEMICAL ABSTRACTS**, vol. 79, 1973,  
Columbus, Ohio, US; abstract no. 66815g,  
**FREZOU, C. ET AL.** page 485 ;
- **CHEMICAL ABSTRACTS**, vol. 89, 1978,  
Columbus, Ohio, US; abstract no. 80938n,  
**KAPOOR, R.C. ET AL.** page 360 ;
- **CHEMICAL ABSTRACTS**, vol. 95, 1981,  
Columbus, Ohio, US; abstract no. 93053u,  
**KALINCAK, M. ET AL.** page 253 ;

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 569 132 B1**

## Description

[0001] The present invention concerns improvements in radiolabelling, and more especially it concerns improved radioisotope complexes.

[0002] Because of their high biological specificity, certain macromolecules such as monoclonal antibodies have been used to target radioisotopes to specific *in vivo* sites for imaging for diagnostic purposes or for therapy. The use of the metastable isotope of technetium  $^{99m}\text{Tc}$ , in diagnostic nuclear medicine is well established, and the beta-emitting isotopes of rhenium  $^{186}\text{Re}$ ,  $^{188}\text{Re}$  and  $^{189}\text{Re}$  can be used therapeutically.

[0003] A number of methods for attaching technetium to macromolecules have been described in the scientific and patent literature. We refer to our EPA 0 384 769 which discusses this area, and teaches methods of modifying macromolecules to permit more ready linking to radioisotope complexes. For example, the method currently preferred in the art for preparing the radiolabelled macromolecule is to reduce the pertechnetate ion  $\text{Tc}^{\text{VII}}\text{O}_4^-$  in the presence of a chelating precursor, to form a labile Tc-precursor complex which is then reacted with a metal binding group on a modified protein to form a Tc-protein conjugate. A number of chelating precursors of this type have been described for technetium which include sodium glucoheptonate, sodium tartrate, sodium gluconate, sodium saccharate and sodium 1,1,3,3-propylenetetraphosphonate

[0004] The presently favoured chelating precursor is sodium glucoheptonate. Use of Tc-glucoheptonate to radiolabel a protein which has been functionally modified with hydrazino-nicotinamide (SHNH) groups as disclosed in the above-mentioned EPA 0384 769 requires an incubation of 60 minutes, and although radiolabelling yields >95% can be achieved, this is at a rather low specific activity of <10mCi/mg protein. It is an aim of the present invention to improve upon the time required for incubation and/or the specific activity, by providing a novel Tc-complex.

[0005] The present invention provides a complex of technetium with the ligand L



L

where

R is hydrogen, hydroxyl, alkyl, hydroxyalkyl, or alkylcarboxy, or R and  $\text{R}^1$  together may form a mono-, di-, tri-, or tetra-methylene radical, or R and  $\text{R}^2$  together may form a mono-, di-, tri-, or tetra-methylene radical, and  $\text{R}^1$  and  $\text{R}^2$  may be the same or different and are selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, hydroxyalkyl, carboxy, carboxyalkyl, aminoalkyl, thioalkyl, aryl or  $\text{R}^1$  and  $\text{R}^2$  together may form a tetra- or penta-methylene radical, and  $\text{R}^3$  and  $\text{R}^4$  and  $\text{R}^5$  may be the same or different and are selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, hydroxyalkyl, carboxy, carboxyalkyl, provided that the least one of  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  is hydroxyalkyl, and n is equal to 0, 1 or 2.

[0006] Preferably, when R is alkyl or substituted alkyl, it is of 1 to 3 carbon atoms. Preferably, when  $\text{R}^1$  and  $\text{R}^2$  are alkyl or substituted alkyl, they are 1 to 4 carbon atoms. Preferred aryl groups are phenyl and benzyl. Preferably, when  $\text{R}^3$  and  $\text{R}^4$  and  $\text{R}^5$  are alkyl or substituted alkyl groups they are of 1 to 3 atoms.

[0007] Preferably, at least one of R,  $\text{R}^1$  and  $\text{R}^2$  is hydrogen and at least one of  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  is hydroxymethyl. A particularly preferred ligand is N-[tris(hydroxymethyl)methyl]glycine, also known as tricine, which name will be used hereinafter. Other desirable ligands L are those in which R,  $\text{R}^1$  and  $\text{R}^2$  are all hydrogen,  $\text{R}^3$  is hydrogen, methyl or ethyl, and  $\text{R}^4$  and  $\text{R}^5$  are hydroxymethyl or 2-hydroxyethyl; R,  $\text{R}^1$  and  $\text{R}^2$  are all hydrogen,  $\text{R}^3$  and  $\text{R}^4$  are hydrogen or methyl, and  $\text{R}^5$  is hydroxymethyl or 2-hydroxyethyl. Also desirable are ligands L in which R and  $\text{R}^1$  are both hydrogen,  $\text{R}^2$  is methyl hydroxy, hydroxymethyl, carboxy, carboxymethyl, 2-carboxyethyl, phenyl, benzyl, 1-hydroxyethyl or mercaptomethyl, and  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  are all hydroxymethyl; R is hydrogen,  $\text{R}^1$  and  $\text{R}^2$  are both methyl, and  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  are all hydroxymethyl; R is hydroxy, hydroxymethyl, or carboxymethyl,  $\text{R}^1$  and  $\text{R}^2$  are both hydrogen, and  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  are all hydroxymethyl.

[0008] The invention further provides a method for the formation of the complex of the invention, comprising reducing the pertechnetate ion in the presence of a ligand of general formula L.

[0009] The method of the invention is desirably carried out in aqueous solution, using stannous ion, for example as stannous chloride. It is possible that other reducing systems may be used, however, provided that there is no significant adverse effect upon the purity and stability of the product complex but stannous ion reduction is at present regarded as the best practicable method. The method proceeds well under generally known conditions and at room temperature.


[0010] The invention also provides labelled macromolecules produced from a modified macromolecule and the complex of the invention. It is possible that the ligand L remains as a co-ligand on the labelled macromolecule, but this has not yet been proved.

[0011] Examples of ligands, within the formula L above include ligands of general formula I.



in which R, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and n are as defined above, such as N-[bis(hydroxymethyl)methyl]glycine, hereinafter also called dicine.

[0012] The ligands of formula I may be prepared by methods generally available to the skilled synthetic chemist, suitably by reacting bis(hydroxymethyl)methylamine with a functionalised acid derivative of general formula II



in which R<sup>1</sup>, R<sup>2</sup> and n are as defined above, and X is a reactive group, for example a halogen, methyl- or toluene-sulphonate or trifluoromethyl-sulphonate, in the presence of a base.

[0013] The invention is more particularly described in the Examples below and with reference to the accompanying Figures, of which

Figure 1 is a comparison of the rate of radiolabelling of IgG-SHNH with three different Tc-precursor complexes, at room temperature,

Figure 2 is a comparison of radiolabelling of IgG by two Tc-precursor complexes at varying levels of specific activity, and

Figure 3 is a comparison of radiolabelling serial dilutions of IgG with two Tc-precursor complexes as a function of specific activity.

[0014] The description of the invention below is to be regarded as illustrative and in no way limiting of the invention.

### EXAMPLE 1

#### a) Preparation of a Tricine/SnCl<sub>2</sub> Lyophilized Kit

[0015] 98ml of chromatography grade (glass distilled and filtered) water which had been deoxygenated by boiling and cooling under argon was measured into an acid washed, rinsed and dried 150ml Erlenmeyer flask containing 3.60g of N-[tris(hydroxymethyl)methyl]glycine (tricine). The pH of the solution was adjusted to 7.1 using approximately 2.3ml of 1 N NaOH solution. The flask was sealed with an airtight septa and purged an additional 60 minutes with argon by canula. A solution of SnCl<sub>2</sub>·2H<sub>2</sub>O, 50mg/ml in deoxygenated 0.1 N HCl, was prepared under argon and 80uL added to the tricine solution. One millilitre of the tricine/SnCl<sub>2</sub> solution was transferred by syringe to an argon filled, septa-capped vial, frozen, and subsequently lyophilized. The lyophilized vials were capped and crimped under argon to render a final composition of 36mg tricine and 0.04mg SnCl<sub>2</sub> at pH 7.1.

#### b) Reconstitution of a Tricine/SnCl<sub>2</sub> Lyophilized Kit Formation of <sup>99m</sup>Tc-tricine

[0016] A septa-capped vial of lyophilized tricine/SnCl<sub>2</sub> composition is injected with 1ml of <sup>99m</sup>TcO<sub>4</sub><sup>-</sup> (20mCi/ml) and immediately upon injection shaken vigorously until all the freeze-dried material is dissolved. Upon dissolution the Tc-tricine sample is left for 15 to 30 minutes at room temperature before analysis. Analysis for formation of the Tc-tricine precursor complex is performed on ITLC-SG chromatography plates. Using an 8 x 1cm plate, a 2.5uL sample of the Tc-tricine solution is spotted at 1cm and eluted with saline to yield <1% Tc-colloid at the origin and >99% Tc-tricine at the solvent front. Using a 10 x 1cm plate, a 2.5uL sample of Tc-tricine solution is spotted at 1cm and eluted with a 2:1 acetone:dichloromethane solution to yield >99% <sup>99m</sup>Tc-tricine at the origin and <1% TcO<sub>4</sub><sup>-</sup> at the solvent front.

[0017] Immunoglobulin (IgG) (MW = approximately 155,000) was conjugated with SHNH according to Example 9 of the EPA 0384 769, and was used in the tests described below.

### EXAMPLE 2

[0018] The rate of radiolabelling IgG modified with SHNH was measured with respect to three Tc-precursor complexes: Tc-tricine, Tc-glucoheptonate, and Tc-saccharate. 100uL of the respective Tc-precursor at 15mCi/ml was mixed with an equal volume of IgG-SHNH at 4.9mg/ml and incubated for one hour at room temperature. Each solution was sampled at 1, 10, 20, 30, 40, 50 and 60 minutes and analyzed by ITLC-SG chromatography using standard techniques. In addition, Tc-tricine was mixed with an equal volume of unmodified IgG to measure its non-specific radiolabelling to the protein. The results, presented in Figure 1, clearly demonstrate that within minutes Tc-tricine radiolabels the protein greater than 90% whereas Tc-glucoheptonate requires one hour. Additionally, the extent of radiolabelling reaches a maximum within thirty minutes for Tc-tricine versus Tc-glucoheptonate which again requires one hour. Tc-saccharate

is clearly the least effective radiolabelling precursor for IgG-SHNH. Tc-tricine, in the absence of hydrazino-nicotinamide linkers on the protein, only radiolabels unmodified IgG to a maximum of 4%. Therefore, the utilisation of tricine in the formation of the Tc-precursor complex dramatically improves the labelling of modified IgG over utilising glucoheptonate.

### 5 **EXAMPLE 3**

[0019] The percent yield of radiolabelling IgG modified with SHNH was measured as a function of the specific activity (mCi of  $^{99m}\text{Tc}$  per mg of protein) of the solutions with respect to two Tc-precursors; Tc-glucoheptonate which was the better of the prior art precursors determined according to Example 2 above, and Tc-tricine. Two series of vials containing 100, 50, 20, 10.5 and 2uL of an IgG-SHNH solution (4.9mg/ml in protein) were prepared. To each vial of one series was added 100uL of the respective Tc-precursor and the vials incubated at 27°C for one hour. The test solutions were analysed by ITLC-SG chromatography using standard techniques. The results, presented in Figure 2, demonstrate >90% radiolabelling of the protein for specific activities of Tc-tricine as high as 140mCi/mg versus Tc-glucoheptonate which shows a dramatic decrease in radiolabelling efficiency as the specific activity increases above 25mCi/mg. Therefore, the utilisation of Tc-tricine improves upon the efficiency of radiolabelling low concentrations of protein.

### **EXAMPLE 4**

[0020] The percent yield of radiolabelling IgG modified with SHNH was measured as a function of the specific activity (mCi of  $^{99m}\text{Tc}$  per mg of protein) for dilute solutions of protein with respect to two Tc-precursors: Tc-tricine and Tc-glucoheptonate. From a stock solution of IgG-SHNH, 4.9mg/ml in citrate buffer pH 5.2, a solution of 10x dilution and a solution of 20x dilution with citrate buffer were prepared. A 100uL sample of each protein solution (at 4.9, 0.49 and 0.25mg IgG-SHNH/ml) was mixed with an equal volume of Tc-precursor solution and incubated for one hour at 37°C. The test solutions were analysed by ITLC/SG chromatography using standard techniques. The results, presented in Figure 3, demonstrate that under buffered conditions, Tc-tricine continues to radiolabel modified protein in greater than 90% efficiency at higher specific activities than Tc-glucoheptonate.

### **EXAMPLE 5**

#### 30 **Synthesis of N-[bis(hydroxymethyl)methyl]glycine, Dicine**

[0021] Serinol (2.5g, 26mMol), chloroacetic acid (2.41g, 26mMol) and NaOH (3.2ml 10N, 52mMol) were dissolved in 25ml water and stirred at room temperature for 16h. The solution was concentrated on a rotoevaporator, and the resulting glass was redissolved in methanol. Addition of acetone gave a white solid (2g, 51%) which was recrystallised from methanol/ethyl acetate. Mass spec calculated for  $\text{C}_5\text{H}_{11}\text{NO}_4$ : 149; found: 150 ( $M + 1$ );  $^1\text{H}$  NMR in  $\text{D}_2\text{O}$  (.75% TMS): 3.85 (m, 4H), 3.80 (s, 2H), 3.45 (m, 1H).

### **EXAMPLE 6**

#### 40 **Synthesis of N-hydroxyethyl-glycine, Monocine**

[0022] 1.0g of glyoxylic acid (10.85mmol), 0.83ml of ethanolamine (13.85mmol), and 0.34g of sodium cyanoborohydride (5mmol) were stirred in methanol at room temperature for 48 hours. 1.0ml of 12N HCl (10.85mmol) was slowly added to the solution, which was then concentrated on a rotoevaporator. Addition of absolute ethanol with rapid stirring gave a white solid which was collected on a frit and dried in vacuo. FAB Mass spec calculated for  $\text{C}_4\text{H}_9\text{NO}_3$ : 119; found: 142 ( $m + \text{Na}$ ), 164 ( $m + 2\text{Na}$ );  $^1\text{H}$  NMR in  $\text{D}_2\text{O}$ : 3.85 (t, 5, 2H), 3.67 (s, 2H), 3.23 (t, 5, 2H).

### **EXAMPLE 7**

#### 50 **Synthesis of N-[tris(hydroxymethyl)methyl]alanine, Methyltricine**

[0023] 2.5g of 2-bromopropionic acid (16.4mmol) and 1.6ml of 10N NaOH (16.4mmol) were dissolved in 25ml of water and 1.98g of N-[tris(hydroxymethyl)methyl]amine (16.4mmol) were added with stirring. The solution was stirred at 80°C for 6 hours during which 16ml of 1N NaOH were added dropwise. The solvent was removed by rotoevaporation and the resulting glass was dried overnight in vacuo. Mass spec calculated for  $\text{C}_7\text{H}_{15}\text{NO}_5$ : 193; found: 194 ( $m + 1$ ), 216 ( $m + \text{Na}$ );  $^1\text{H}$  NMR in  $\text{D}_2\text{O}$ : 3.66 (q, 7, 1H), 3.21 (s, 6H), 1.13 (d, 7, 3H).

**EXAMPLE 8****Synthesis of N-[tris(hydroxymethyl)methyl]- $\beta$ -alanine ( $\beta$ -Methyltricine)**

[0024] 10g of Tris (8.26mMol) and 1.0ml of acrylonitrile (16mMol) were stirred in methanol at 70°C for 48 hours. The solvent was removed on a rotoevaporator and absolute ethanol was added to the resulting glass. The unreacted Tris which precipitated from solution was filtered and the mother liquor was filtered through a short plug of silica gel. Concentration of the solution gave a white crystalline solid A (0.86g, 60%).  $^1\text{H}$  NMR; 3.58 (s, 6H), 2.96 (t, 7, 2H), 2.65 (t, 7, 2H).

[0025] 0.25G of A (14mMol) was refluxed in concentrated HCl for 16 hours. The solvent was stripped on a rotoevaporator and the resulting residue was dried overnight under vacuum at 80°C. The solution was evaporated on a rotoevaporator to give an off-white solid, N-[tris-(hydroxymethyl)methyl]- $\beta$ -alanine ammonium chloride.

**EXAMPLE 9****Preparation of Tc-L Precursor Solution**

[0026] An aqueous precursor solution of ligand L, eg tricine, at 72mg/ml concentration was prepared in de-oxygenated, metal-free water. The precursor stock solution was adjusted to pH7.1 with 1N NaOH solution. A second stock solution of  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ , 10mg/ml in 0.1N HCl, was prepared and added to the precursor stock solution to make it 100ug/ml in  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ . The precursor/ $\text{SnCl}_2$  solution was mixed in equal proportions with  $^{99\text{m}}\text{TcO}_4^-$  (30mCi/ml). After a few minutes at room temperature, analysis for the formation of the Tc-ligand precursor complex was performed on ITLC-SG chromatography plates. Using an 8x1cm plate, a 2.5uL sample of the Tc-precursor solution is spotted at 1cm and eluted with saline to yield Tc-colloid at the origin and Tc-precursor complex at the solvent front. Using a 10x1cm plate, a 2.5uL sample of the Tc-precursor solution is spotted at 1cm and eluted with methylethylketone or 2:1 acetone:dichloromethane solution to yield Tc-precursor at the origin and  $^{99\text{m}}\text{TcO}_4^-$  at the solvent front.

[0027] Results presented in Table 1 as % yield of technetium species in solution clearly demonstrate that this method is general to technetium complexes of ligands L exemplified in Examples 1, 5, 6 and 7. Functional substitutions on the tris(hydroxymethyl)methyl group or the glycine still yield quantitative formation of the Tc-precursor complex within minutes at room temperature. These solutions are suitable for protein labelling with no further modification.

**EXAMPLE 10****Radiolabelling of IgG modified with SHNH with Tc-L precursors**

[0028] The efficacy of radiolabelling IgG modified with SHNH (hydrazino-nicotinamide groups, as described in EPA 0384769) was measured with respect to Tc-precursor complexes as generated in Example 9 above. 100uL of the respective Tc-precursor at 15mCi/ml was mixed with an equal volume of IgG-SHNH, 4.9mg/ml in 20mM citrate 100mM NaCl buffer pH5.2, and incubated for one hour at room temperature. The solution was sampled at 60 minutes and analysed by thin layer chromatography using ITLC-SG plates, 1x8cm, and saline eluant. Tc-labelled IgG-SHNH adheres to the origin of the plate and Tc-precursors as well as  $^{99\text{m}}\text{TcO}_4^-$  elute to the solvent front.

[0029] The results, presented in Table 1 as % yield of Tc-IgG-SHNH (and corrected for Tc-colloid), clearly demonstrate that Tc-precursors formulated from polyhydroxy analogues of ligand L quantitatively radiolabel IgG-SHNH. Additionally, alkyl modification of glycine in ligand L to alanine, as exemplified in methyltricine, still yields quantitative radiolabelling of IgG-SHNH although the efficiency is decreased at room temperature. Therefore, the general use of polyhydroxy amino acid analogues of ligand L for the formation of Tc-precursor complexes and subsequent radiolabelling of proteins modified with SHNH is demonstrated.

TABLE 1

Formation of Tc-precursor Complexes and Radiolabelling of IgG-SHNH				
Sampl	% Yield of Technetium Species in Solution			% Yield of Tc-IgG-SHNH
	TC-precursor	Tc-colloid	TCO <sub>4</sub>	12.5mCi/mg
Tc-Tricine	98.5	0.2	1.3	97.4
Tc-Methyltricine	94.9	0.8	4.3	90.1
Tc-Dicine	99.3	0.1	0.6	98.9
Tc-Monocine	84.1	13.9	2	73.3
Tc-β-Methyltricine	57.6	18.2	24.2	75.4 *

\* &gt;60 min

## Claims

1. A complex of <sup>99m</sup>Tc with the ligand L,



L

where


R is hydrogen, hydroxyl, alkyl, hydroxyalkyl, or alkylcarboxy, or R and R<sup>1</sup> together may form a mono-, di-, tri-, or tetra-methylene radical, or R and R<sup>2</sup> together may form a mono-, di-, tri-, or tetra-methylene radical, and R<sup>1</sup> and R<sup>2</sup> may be the same or different and are selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, hydroxyalkyl, carboxy, carboxyalkyl, aminoalkyl, thioalkyl, aryl or R<sup>1</sup> and R<sup>2</sup> together may form a tetra- or penta-methylene radical, and R<sup>3</sup> and R<sup>4</sup> and R<sup>5</sup> may be the same or different and are selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, hydroxyalkyl, carboxy, carboxyalkyl, provided that the least one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is hydroxyalkyl, and n is equal to 0, 1 or 2.

2. A complex according to claim 1, wherein the ligand, at least one of R, R<sup>1</sup> and R<sup>2</sup> is hydrogen.
3. A complex according to claim 2, wherein in the ligand, at least two of R, R<sup>1</sup> and R<sup>2</sup> are hydrogen.
4. A complex according to claim 1, wherein in the ligand, at least one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is hydroxymethyl.
5. A complex according to claim 1, wherein the ligand L is tricine.
6. A complex according to claim 1, wherein the ligand L is monocine.
7. A complex according to claim 1, wherein the ligand L is dicine.
8. A complex according to claim 1, wherein the ligand L is methyltricine.
9. A method of forming the complex of claim 1, comprising the reduction of the pertechnetate ion in the presence of a ligand of general formula L.
10. A radiolabelled macromolecule comprising the product of a modified macromolecule with a complex according to any of claims 1 to 8.
11. A radiolabelled macromolecule according to claim 10, wherein the modified macromolecule is a conjugate of the macromolecule and a compound having at least one free hydrazine or hydrazide group.

12. The use of a ligand of formula L as defined in claim 1, for the formation of complexes with radioisotopes.

### Patentansprüche

1.  $^{99m}\text{Tc}$ -Komplex mit dem Liganden L,



L

worin

R Wasserstoff, Hydroxyl, Alkyl, Hydroxyalkyl oder Alkylcarboxy ist oder R und  $\text{R}^1$  zusammen ein Mono-, Di-, Tri- oder Tetramethylenradikal bilden können oder R und  $\text{R}^2$  zusammen ein Mono-, Di-, Tri- oder Tetramethylenradikal bilden können und

$\text{R}^1$  und  $\text{R}^2$  gleich oder unterschiedlich sein können und aus Wasserstoff, Hydroxy, substituiertem oder nicht-substituiertem Alkyl, Hydroxyalkyl, Carboxy, Carboxyalkyl, Aminoalkyl, Thioalkyl oder Aryl ausgewählt werden oder  $\text{R}^1$  und  $\text{R}^2$  zusammen ein Tetra- oder Pentamethylenradikal bilden können und

$\text{R}^3$  und  $\text{R}^4$  und  $\text{R}^5$  gleich oder unterschiedlich sein können und aus Wasserstoff, Hydroxy, substituiertem oder nichtsubstituiertem Alkyl, Hydroxyalkyl, Carboxy oder Carboxyalkyl ausgewählt werden, vorausgesetzt dass mindestens eines von  $\text{R}^3$ ,  $\text{R}^4$  und  $\text{R}^5$  Hydroxyalkyl ist und n gleich 0, 1 oder 2 ist.

2. Komplex nach Anspruch 1, worin in dem Liganden mindestens eines von R,  $\text{R}^1$  und  $\text{R}^2$  Wasserstoff ist.

3. Komplex nach Anspruch 2, worin in dem Liganden mindestens zwei von R,  $\text{R}^1$  und  $\text{R}^2$  Wasserstoff sind.

4. Komplex nach Anspruch 1, worin in dem Liganden mindestens eines von  $\text{R}^3$ ,  $\text{R}^4$  und  $\text{R}^5$  Hydroxymethyl ist.

5. Komplex nach Anspruch 1, worin der Ligand L Tricin ist.

6. Komplex nach Anspruch 1, worin der Ligand L Monocin ist.

7. Komplex nach Anspruch 1, worin der Ligand L Dicin ist.

8. Komplex nach Anspruch 1, worin der Ligand L Methyltricin ist.

9. Verfahren zum Bilden des Komplexes nach Anspruch 1, das die Reduktion des Pertechnetat-Ions bei Vorliegen eines Liganden der allgemeinen Formel L umfasst.


10. Radiomarkiertes Makromolekül, welches das Produkt eines modifizierten Makromoleküls mit einem Komplex nach einem der Ansprüche 1 bis 8 umfasst.

11. Radiomarkiertes Makromolekül nach Anspruch 10, worin das modifizierte Makromolekül ein Konjugat des Makromoleküls und einer Verbindung mit mindestens einem freien Hydrazin oder einer Hydrazingruppe ist.

12. Verwendung eines Liganden der Formel 1 nach Anspruch 1 für die Bildung von Komplexen mit Radioisotopen.

### Revendications

1. Complexe de  $^{99m}\text{Tc}$  avec le ligand L,



L

où

R est un hydrogène, un hydroxyle, un alkyle, un hydroxyalkyle, ou un alkylcarboxy, ou bien R et  $\text{R}^1$  ensemble peuvent former un radical mono-, di-, tri-, ou tétra-méthylène, ou bien R et  $\text{R}^2$  ensemble peuvent former un radical mono-, di-, tri-, ou tétra-méthylène, et


R<sup>1</sup> et R<sup>2</sup> peuvent être les mêmes ou différents et sont sélectionnés à partir d'un hydrogène, d'un hydroxy, d'un alkyle substitué ou non substitué, d'un hydroxyalkyle, d'un carboxy, d'un carboxyalkyle, d'un aminoalkyle, d'un thioalkyle, d'un aryle ou bien R<sup>1</sup> et R<sup>2</sup> ensemble peuvent former un radical tétra- ou penta-méthylène, et R<sup>3</sup> et R<sup>4</sup> et R<sup>5</sup> peuvent être les mêmes ou différents et sont sélectionnés à partir d'un hydrogène, d'un hydroxy, d'un alkyle substitué ou non substitué, d'un hydroxyalkyle, d'un carboxy, d'un carboxyalkyle, dans la mesure où au moins l'un de R<sup>3</sup>, R<sup>4</sup> et R<sup>5</sup> est un hydroxyalkyle, et n est égal à 0, 1 ou 2.

2. Complexe selon la revendication 1, dans lequel le ligand, au moins l'un de R, R<sup>1</sup> et R<sup>2</sup> est un hydrogène.
3. Complexe selon la revendication 2, dans lequel dans le ligand, au moins deux de R, R<sup>1</sup> et R<sup>2</sup> sont un hydrogène.
4. Complexe selon la revendication 1, dans lequel dans le ligand, au moins l'un de R<sup>3</sup>, R<sup>4</sup> et R<sup>5</sup> est un hydroxyméthyle.
5. Complexe selon la revendication 1, dans lequel le ligand L est de la tricine.
6. Complexe selon la revendication 1, dans lequel le ligand L est de la monocine.
7. Complexe selon la revendication 1, dans lequel le ligand L est de la dicine.
8. Complexe selon la revendication 1, dans lequel le ligand L est de la méthyltricine.
9. Méthode pour former le complexe de la revendication 1, comprenant la réduction de l'ion de pertechnétate en présence d'un ligand de la formule générale L.
10. Macromolécule radiomarquée comprenant le produit d'une macromolécule modifiée avec un complexe selon l'une quelconque des revendications 1 à 8.
11. Macromolécule radiomarquée selon la revendication 10, dans laquelle la macromolécule modifiée est un conjugué de la macromolécule et d'un composé ayant au moins un groupe hydrazine ou hydrazide libre.
12. Emploi d'un ligand de la formule L telle que définie dans la revendication 1, pour la formation de complexes avec des radio-isotopes.



**FIG.1**


A COMPARISON OF THE RATE OF  
RADIOLABELLING OF IgG-SHNH WITH  
THREE DIFFERENT T<sub>c</sub>-PRECURSOR  
COMPLEXES AT ROOM TEMPERATURE



- ▼ Tc-tricine w/IgG-SHNH
- ▽ Tc-glucoheptonate w/IgG-SHNH
- Tc-saccharate w/IgG-SHNH
- Tc-tricine w/IgG

**FIG.2**

**A COMPARISON OF PROTEIN RADIOLABELLING  
BY TWO Tc - PRECURSOR COMPLEXES AT  
VARYING LEVELS OF SPECIFIC ACTIVITY**



**FIG. 3**

A COMPARISON OF THE RADIOLABELLING OF SERIAL DILUTIONS OF PROTEIN WITH TWO Tc-PRECURSOR COMPLEXES AS A FUNCTION OF SPECIFIC ACTIVITY

